Safety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis during the 96-week, phase III, double-blind, placebo-controlled CLARITY study

被引：0
|
作者：
Cook, S.
Vermersch, P.
Comi, G.
Giovannoni, G.
Rammohan, K.
Rieckmann, P.
Sorensen, P. S.
Chang, P.
Hamlett, A.
Musch, B.
Viglietta, V.
Greenberg, S.
机构：
[1] Univ Med & Dent, Newark, NJ USA
[2] Univ Lille, Lille, France
[3] Univ Vita Salute, Milan, Italy
[4] Barts & London Queen Marys Sch Med & Dent, London, England
[5] Ohio State Univ, Columbus, OH 43210 USA
[6] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[7] Rigshosp, DK-2100 Copenhagen, Denmark
[8] Merck Serono SA, Geneva, Switzerland
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Tabalumab in Patients with Relapsing-Remitting Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
    Silk, Maria
    Nantz, Eric
    NEUROLOGY, 2018, 90
  • [32] Acyclovir treatment of relapsing-remitting multiple sclerosis - A randomized, placebo-controlled, double-blind study
    Lycke, J
    Svennerholm, B
    Hjelmquist, E
    Frisen, L
    Badr, G
    Andersson, M
    Vahlne, A
    Andersen, O
    JOURNAL OF NEUROLOGY, 1996, 243 (03) : 214 - 224
  • [33] A double-blind, placebo-controlled, multicentre study to evaluate dirucotide in relapsing-remitting multiple sclerosis
    Selmaj, K.
    Verco, T.
    Ossanna, M.
    Nilsson, M.
    Ferenczi, L.
    Chappell, A.
    Arfors, L.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S235 - S235
  • [34] Results from the CLARITY Study: a Phase III, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Oral Cladribine in Relapsing-Remitting Multiple Sclerosis (RRMS)
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart D.
    Rammohan, Kottil W.
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Chang, Peter
    Hamlett, Anthony
    Musch, Bruno
    Greenberg, Steven J.
    NEUROLOGY, 2009, 73 (04) : 330 - 330
  • [35] Tolerability profile of cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis: factors contributing to treatment completion overall and in patients with high disease activity in the 96-week CLARITY study
    Vermersch, P.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Kurukulasuriya, N.
    Viglietta, V.
    Chang, P.
    Papasouliotis, O.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2011, 258 : 259 - 259
  • [36] Oral cladribine added to interferon beta-1a for active multiple sclerosis: a 96-week, double-blind, placebo-controlled phase IIb study
    Montalban, X.
    Cohen, B. A.
    Jeffery, D. R.
    Leist, T. P.
    Moses, H.
    Musch, B.
    MULTIPLE SCLEROSIS, 2007, 13 : S245 - S246
  • [37] Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study
    Rammohan, Kottil
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Hamlett, Anthony
    Kurukulasuriya, Nuwan
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2012, 1 (01) : 49 - 54
  • [38] A randomised, placebo-controlled, double-blind, multicentre, phase IIIb study assessing efficacy, safety and tolerability of Rebiff® New Formulation in patients with relapsing-remitting multiple sclerosis
    De Stefano, N.
    Beelke, M.
    JOURNAL OF NEUROLOGY, 2007, 254 : 191 - 191
  • [39] Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
    Kappos, Ludwig
    Gold, Ralf
    Miller, David H.
    MacManus, David G.
    Havrdova, Eva
    Limmroth, Volker
    Polman, Chris H.
    Schmierer, Klaus
    Yousry, Tarek A.
    Yang, Minhua
    Eraksoy, Mefkure
    Meluzinova, Eva
    Rektor, Ivan
    Dawson, Katherine T.
    Sandrock, Alfred W.
    O'Neill, Gilmore N.
    LANCET, 2008, 372 (9648): : 1463 - 1472
  • [40] Safety and Tolerability of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study
    Cook, Stuart
    Comi, Giancarlo
    Rieckmann, Peter
    Rammohan, Kottil
    Soelberg-Soerensenn, Per
    Vermersch, Patrick
    Martin, Emily
    Dangond, Fernando
    Giovannoni, Gavin
    NEUROLOGY, 2016, 86
12345